FOXO4-DRI F4
Senolytic peptide
D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, studied as a senolytic that triggers apoptosis in senescent cells.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Senolytic peptide
- Category
- Mitochondrial & Longevity
- Type
- Single compound
- Abbreviation
- F4
- Development and regulatory status
- Not approved; preclinical research peptide
What researchers study
D-retro-inverso (all-D-amino-acid) peptide designed to disrupt the interaction between FOXO4 and p53. In senescent cells this reportedly causes p53 to leave the nucleus and triggers apoptosis, so it is classed as a senolytic.
Research areas
- Senescent-cell apoptosis in cell culture
- FOXO4-p53 interaction studies
- Chemotoxicity and ageing models in mice
- Comparison with other senolytic approaches
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
In senescent cells the FOXO4 peptide selectively caused p53 nuclear exclusion and cell-intrinsic apoptosis
- rodent
It neutralized doxorubicin-induced chemotoxicity and restored fitness, fur density and renal function in fast-ageing and naturally aged mice
